CompletedPhase 4

Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes

Iran

Plain-language summary

The use of topical Cyclosporine A early after an episode of endothelial graft rejection after penetrating keratoplasty and continuing its administration for 6 months can reduce the course of that episode and recurrence of the rejection.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Penetrating keratoplasty in eyes without vascularization Exclusion Criteria: * History of previous intraocular surgery

What they're measuring

The rate of rejection after drop sessation

Timeframe: 3 years

Trial details

NCT IDNCT01028443

SponsorShahid Beheshti University of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Endothelial Graft Rejection trials